Literature DB >> 11133719

Thermolabile MTHFR genotype and retinal vascular occlusive disease.

M Cahill1, M Karabatzaki, C Donoghue, R Meleady, L A Mynett-Johnson, D Mooney, I M Graham, A S Whitehead, D C Shields.   

Abstract

BACKGROUND: Raised levels of total plasma homocysteine (tHcy) are associated with an increased risk of retinal vascular occlusive disease. A thermolabile form of a pivotal enzyme in homocysteine metabolism, methylenetetrahydrofolate reductase (MTHFR), has been associated with vascular occlusive disease and raised tHcy levels. The relation between thermolabile MTHFR genotype, tHcy, and retinal vascular occlusive disease has not been determined.
METHODS: A retrospective case-control study involving hospital based controls and cases with retinal vascular occlusions in whom tHcy levels had been determined was undertaken. Genotyping for the MTHFR 677 C-T mutation that specifies the thermolabile form of the enzyme was performed by established methods in all subjects. The relation between homozygosity for thermolabile MTHFR genotype (TT), raised tHcy levels, and risk of retinal vascular occlusive disease was examined.
RESULTS: 87 cases of retinal vascular occlusive disease (mean age 68.7 years) comprising 26 cases of retinal artery occlusion and 61 of retinal vein occlusion were compared with 87 controls (mean age 70.2 years). The TT genotype did not confer a significantly increased risk of retinal vascular occlusive disease. The mean tHcy level was significantly higher in the cases than in the controls (p<0.0001). Overall, and in both the cases and controls, the frequency of the TT genotype was higher in those with normal tHcy levels than in those with increased levels of tHcy. However, the TT genotype did not significantly alter the risk of increased tHcy levels in these patients.
CONCLUSIONS: The TT genotype is not associated with an increased risk of retinal vascular occlusive disease or increased tHcy levels in this group of elderly patients. In older patients, nutritional rather than genetic factors may be more important in increasing tHcy levels, a known risk factor for retinal vascular occlusive disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11133719      PMCID: PMC1723690          DOI: 10.1136/bjo.85.1.88

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  31 in total

1.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease.

Authors:  M Cahill; M Karabatzaki; R Meleady; H Refsum; P Ueland; D Shields; D Mooney; I Graham
Journal:  Br J Ophthalmol       Date:  2000-02       Impact factor: 4.638

2.  Homocystinuria presenting as central retinal artery occlusion and longstanding thromboembolic disease.

Authors:  W vd Berg; F D Verbraak; P J Bos
Journal:  Br J Ophthalmol       Date:  1990-11       Impact factor: 4.638

3.  Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation.

Authors:  A Loewenstein; M Goldstein; A Winder; M Lazar; A Eldor
Journal:  Ophthalmology       Date:  1999-09       Impact factor: 12.079

4.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase.

Authors:  P Frosst; H J Blom; R Milos; P Goyette; C A Sheppard; R G Matthews; G J Boers; M den Heijer; L A Kluijtmans; L P van den Heuvel
Journal:  Nat Genet       Date:  1995-05       Impact factor: 38.330

5.  Homocysteine and other thiols in plasma and urine: automated determination and sample stability.

Authors:  T Fiskerstrand; H Refsum; G Kvalheim; P M Ueland
Journal:  Clin Chem       Date:  1993-02       Impact factor: 8.327

6.  Hyperhomocysteinemia in retinal artery and retinal vein occlusion.

Authors:  E M Wenzler; A J Rademakers; G H Boers; J R Cruysberg; C A Webers; A F Deutman
Journal:  Am J Ophthalmol       Date:  1993-02-15       Impact factor: 5.258

7.  Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification.

Authors:  P Goyette; J S Sumner; R Milos; A M Duncan; D S Rosenblatt; R G Matthews; R Rozen
Journal:  Nat Genet       Date:  1994-06       Impact factor: 38.330

8.  Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency.

Authors:  P Goyette; P Frosst; D S Rosenblatt; R Rozen
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

9.  Vitamin status and intake as primary determinants of homocysteinemia in an elderly population.

Authors:  J Selhub; P F Jacques; P W Wilson; D Rush; I H Rosenberg
Journal:  JAMA       Date:  1993-12-08       Impact factor: 56.272

10.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.

Authors:  C J Boushey; S A Beresford; G S Omenn; A G Motulsky
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272

View more
  6 in total

Review 1.  Thrombophilia: genetic polymorphisms and their association with retinal vascular occlusive disease.

Authors:  M Chak; G R Wallace; E M Graham; M R Stanford
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

2.  NONICHEMIC CENTRAL RETINAL VEIN OCCLUSION ASSOCIATED WITH HEREDITARY THROMBOPHYLIA.

Authors:  Andreea Dana Fişuş; Doina Suzana Pop; Monica Blanka Rusu; Florina Vultur; Karin Ursula Horvath
Journal:  Rom J Ophthalmol       Date:  2015 Jul-Sep

3.  Hyperhomocysteinemia and central retinal vein occlusion in Iranian population.

Authors:  Sasan Moghimi; Zahra Najmi; Hooshang Faghihi; Reza Karkhaneh; Mohammad Sadegh Farahvash; Maryam Maghsoudipour
Journal:  Int Ophthalmol       Date:  2007-07-17       Impact factor: 2.031

4.  Methylenetetrahydrofolate reductase C677T mutation and risk of retinal vein thrombosis.

Authors:  Mohammad Soleiman Soltanpour; Zahra Soheili; Ali Shakerizadeh; Ali Akbar Pourfathollah; Shahram Samiei; Reza Meshkani; Mohammad Shahjahani; Abbas Karimi
Journal:  J Res Med Sci       Date:  2013-06       Impact factor: 1.852

Review 5.  Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities.

Authors:  Jiri Rehak; Matus Rehak
Journal:  Curr Eye Res       Date:  2008-02       Impact factor: 2.424

6.  Hyperhomocysteinia is a risk factor for retinal venous occlusion: a case control study.

Authors:  Fahad Al Wadani; Rajiv Khandekar; Gigani Salim; Mohammed Al Ali; Salman Ramzi
Journal:  Indian J Ophthalmol       Date:  2014-03       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.